Northland Capital Partners has acted as Joint Broker in a US$25,000,000 fund raise for Motif Bio (MTFB.L). The proceeds of the placing will fund the expenses to be incurred in conducting the two Phase 3 clinical trials of iclaprim for the treatment of ABSSSI, including the completion of the REVIVE-1 trial and general working capital.
Trusted partner to
Northland Capital Partners Ltd (“Northland”) is an independent institutional stockbroker and corporate adviser. The company enables growth companies to access capital and offers a full nomad service to AIM-quoted and small and mid-cap companies. It has excellent connections with investors, providing them with equity research, advice and trading services.
Northland, a privately owned company managed and controlled by its employees, has assembled a team of highly motivated and experienced professionals that aims to deliver unparalleled service to our clients. It has a strong track record in advising and raising funds for growth companies.
Northland always provides innovative ideas and solutions enabling our clients to fulfil their long-term growth ambitions in a wide range of sectors including Healthcare, TMT, Consumer, Resources and Support Services. As the most successful growth market in the world, AIM is an important platform for helping small companies raise capital.
Northland is a Nominated Adviser and Broker for the AIM Market and a Financial adviser for Main Market Standard listings. Through our global corporate, investor and intermediary network, we can add further value for our clients by identifying vendors or acquirers of assets and businesses.
Sales and Broking
Northland’s Institutional Sales and Broking team provides unique investment ideas to meet client investment objectives and fund mandates through the combination of market knowledge, dedicated research and a wealth of experience.
Northland focuses on providing comprehensive and timely research on its corporate clients. Our research coverage is underpinned by a strong track record across a number of sectors including Natural Resources; Technology, Media and Telecoms; Healthcare; and Consumer, Leisure and Gaming.
Northland Capital Partners has acted as Joint Broker in a £4,500,000 fund raise for Ascent Resources (AST.L). The proceeds of the placing will allow the Company to recomplete the Pg-10 and Pg-11a wells, connect the two wells to the existing central treatment station (CPP), refurbish the CPP, provide working capital and repay the £871,510 loan to Henderson Loan Facility.
Northland Capital Partners has acted as Broker in a £3,500,000 fund raise for ImmuPharma (IMM.L). The placing was undertaken to satisfy new institutional demand and broaden its share register and strengthen its financial position to support its general working capital requirements.
Northland Capital Partners has acted as Joint Broker in a £300,000 fund raise for Starcom (STAR.L). The proceeds of the placing will provide working capital to meet a delay in payments due in Q416 which will now be made in early 2017.
Northland Capital Partners Limited
60 Gresham Street, 4th Floor
London, EC2V 7BB
Tel: (020) 3861 6625
Fax: (020) 7600 5975